Predictors of mortality of idiopathic pulmonary fibrosis

European Review for Medical and Pharmacological Sciences

Volumn 12, Issue 2, 2008, Pages 97-104

  Carbone, R ^a   Balleari, E ^a   Grosso, M ^a   Montanaro, F ^b   Bottino, Giovanni ^a   Ghio, R ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Idiopathic pulmonary fibrosis; Mortality; Outcome; Prognostic factors; Survival

Indexed keywords

CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL PNEUMONIA; LUNG TRANSPLANTATION; MORTALITY; PRACTICE GUIDELINE; PREDICTION; PROGNOSIS; REVIEW; TREATMENT INDICATION;

ELIGIBILITY DETERMINATION; HUMANS; LUNG TRANSPLANTATION; PATIENT SELECTION; PROGNOSIS; PULMONARY FIBROSIS; RISK FACTORS; SURVIVAL RATE;

EID: 45149128395     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. AMERICAN THORACIC SOCIETY, EUROPEAN RESPIRATORY SOCIETY. Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement. Am J Respir Crit Care Med 2000; 161: 646-664.
2. GRIBBIN J, HUBBARD RB, LE JEUNE I, SMITH CJ, WEST J, TATA LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61: 980-985.
3. JEGAL Y, KIM DS, SHIM TS, LIM CM, DO LEE S, KOH Y, KIM WS, KIM WD, LEE JS, TRAVIS WD, KITAICHI M, COLBY TV. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171: 639-644.
4. NICHOLSON AG, COLBY TV, DU BOIS RM, HANSELL DM, WELLS AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000; 162: 2213-2217.
5. DANIIL ZD, GILCHRIST FC, NICHOLSON AG, HANSELL DM, HARRIS J, COLBY TV, DU BOIS RM. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999; 160: 899-905.
6. WALTER N, COLLARD HR, KING TE. Current perspectives on the treatment of idiopathic pulmonary fibrosis, Proc Am Thorac Soc 2006; 3: 330-338.
7. BJORAKER JA, RYU JH, EDWIN MK, MYERS JL, TAZELAAR HD, SCHROEDER DR, OFFORD KP. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157: 199-203.
8. FLAHERTY KR, MUMFORD JA, MURRAY S, KAZEROONI EA, GROSS BH, COLBY TV, TRAVIS WD, FLINT A, TOEWS GB, LYNCH JP 3RD, MARTINEZ FJ. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 543-548.
9. FLAHERTY KR, ANDREI AC, MURRAY S, FRALEY C, COLBY TV, TRAVIS WD, LAMA V, KAZEROONI EA. GROSS BH, TOEWS GB, MARTINEZ FJ. Idiopathic pulmonary fibrosis: Prognostic value of changes in physiology and six-minute test. Am J Respir Crit Care Med. 2006; 174: 803-809.
10. LAMA VN, FLAHERTY KR, TOEWS GB, COLBY TV, TRAVIS WD, LONG Q, MURRAY S, KAZEROONI EA, GROSS BH, LYNCH JP 3RD, MARTINEZ FJ. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 1084-1090.
11. HAMADA K, NAGAI S, TANAKA S, HANDA T, SHIGEMATSU N, NAGAO T, MISHIMA M, KITAICHI M, IZUMI T. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007; 131: 650-656.
12. MARTINEZ FJ, FLAHERTY K. Pulmonary function testing in idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3: 315-321.
13. LETTIERI CJ, NATHAN SD, BARNETT SD, AHMAD S, SHORR AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746-752.
14. CARBONE R. MONTANARO F, MONSELISE A, GHIO R. BAUGHMAN R. Cardiac performance in the prognosis of interstitial lung diseases. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 237.
15. GREENE KE, KING TE JR, KUROKI Y, BUCHER-BARTELSON B, HUNNINGHAKE GW, NEWMAN LS, NAGAE H, MASON RJ. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002; 19: 439-446.
16. TABUENA RP, NAGAI S, TSUTSUMI T, HANDA T, MINORU T, MIKUNIYA T, SHIGEMATSU M, HAMADA K, IZUMI T, MISHIMA M. Cell profiles of bronchoalveolar lavage fluid as prognosticators of idiopathic pulmonary fibrosis/usual interstitial pneumonia among Japanese patients. Respiration 2005; 72: 490-498.
17. ENOMOTO N, SUDA T, KATO M, KAIDA Y, NAKAMURA Y, IMOKAWA S, IDA M, KIDA K. Quantitative analysis of fibroblastic foci in usual interstitial pneumonia. Chest 2006; 130: 22-29.
18. TIITTO R BLOIGU R, HEISKANEN U, PAAKKO P, KINNULA VL, KAARTEENAHO-WIIK R. Relationship between histopathological features and the course of idiopathic pulmonary fibrosis/usual interstitial pneumonia. Thorax 2006; 61: 1091-1095.
19. FLAHERTY KR, COLBY TV, TRAVIS WD, TOEWS GB, MUMFORD J, MURRAY S, THANNICKAL VJ, KAZEROONI EA, GROSS BH, LYNCH JP 3RD, MARTINEZ FJ. Fibroblastic foci in usual interstitial pneumonia: Idiopathic versus collagen vascular disease. Am J Respir Crit Care Med 2003; 167: 1410-1415.
20. 111In-octreotide in idiopathic pulmonary fibrosis. J Nucl Med 2006; 47: 1281-1287.
21. KING TE JR, TOOZE JA, SCHWARTZ MI, BROWN KR, CHERNIACK RM. Predicting survival in idiopathic pulmonary fibrosis scoring system and survival model. Am J Respir Crit Care Med 2001; 164: 1171-1181.
22. WELLS AU, DESAI SR, RUBENS MB, GOH NS, CRAMER D, NICHOLSON AG, COLBY TV, DU BOIS RM, HANSELL DM. Idiopathic pulmonary fibrosis: A composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Grit Care Med 2003; 167: 962-969.
23. LATSI PI, DU BOIS RM, NICHOLSON AG, COLBY BISIRTZOGLOU D, NIKOLAKOPOULOU A, VEERARAGHAVAN S, HANSELL DM, WELLS AU. Fibrotic idiopathic interstitial pneumonia: The prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168: 531-537.
24. COLLARD HR, KING TE Jr, BARTELSON BB, VOURLEKIS JS, SCHWARZ MI, BROWN KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538-542.
25. KONDOH Y, TANIGUCHI H, KAWABATA Y, YOKOI T, SUZUKI K, TAKAGI K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 1993; 103: 1808-1812.
26. KIM DS, COLLARD HR, KING TE, Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3: 285-292.
27. MARTINEZ FJ, SAFRIN S, WEYCKER D, STARKO KM, BRADFORD WZ, KING TE Jr, FLAHERTY KR, SCHWARTZ DA, NOBLE PW, RAGHU G, BROWN KK; IPF STUDY GROUP. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142: 963-967.
28. RUDD RM, PRESCOTT RJ, CHALMERS JC, JOHNSTON ID; FIBROSING ALVEOLITIS SUBCOMMITTEE OF THE RESEARCH COMMITTEE OF THE BRITISH THORACIC SOCIETY. British Thoracic Society Study on cryptogenic fibrosing alveolitis: Besponse to treatment and survival. Thorax 2007; 62: 62-66. Erratum in: Thorax 2007; 62: 371.
29. COLLARD HR, RYU JH, DOUGLAS WW, SCHWARZ MI, CURRAN-EVERETT D, KING TE Jr, BROWN KK. Combined corticosteroid and cyclophosfamide therapy does not alter survival idiopathic pulmonary fibrosis. Chest 2004; 125: 2169-2174.
30. RAGHU G, BROWN KK, BRADFORD WZ, STARKO KM, NOBLE PW, SCHWARTZ DA, KING TE Jr; IDIOPATHIC PULMONARY FIBROSIS STUDY GROUP. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-133.
31. MARTINEZ FJ, KEANE MP. Update in diffuse parenchymal lung diseases 2005. Am J Resp Crit Care Med 2006; 173: 1066-1071.
32. LUPPI F, CERRI S, RICHELDI L. Steroid and/or other immunosuppressive therapies in idiopathic interstitial pneumonias: Have they still a role? Sarcoidosis Vasc Diffuse Lung Dis 2005; 22: S74-S84.
33. AZUMA A, NUKIWA T, TSUBOI E, SUGA M, ABE S, NAKATA K, TAGUCHI Y, NAGAI S, ITOH H, OHI M, SATO A, KUDOH S. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-1047.
34. THABUT G, MAL H, CASTIER Y, GROUSSARD O, BRUGIERE O, MARRASH-CHAHIA R, LESECHE G, FOURNIER M. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 2003; 126: 469-475.
35. BARST RJ, MCGOON M, TORBICKI A, SITBON O, KROWKA MJ, OLSCHEWSKI H, GAINES. Diagnosis and differential assessment of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 40S-47S.
36. MCGOON M, GUTTERMAN D, STEEN V, BARST R, MCCRORY DC, FORTIN TA, LOYD JE; AMERICAN COLLEGE OF CHEST PHYSICIANS. Screening early detection, and diagnosis of pulmonary arterial hypertension. ACCP evidence-based clinical practice guidelines. Chest 2004; 126: 14S-34S,
37. STEPHEN B, DALAL P, BERGER M, SCHWEITZER P, HECHT S. Noninvasive estimation of pulmonary artery diastolic pressure in patients with tricuspid regurgitation by Doppler echocardiography. Chest 1999; 116: 73-77.